P/E ratio for Amedisys (AMED)
P/E ratio as of June 2023 (TTM): 26.8
According to Amedisys's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 26.763. At the end of 2021 the company had a P/E ratio of 25.3.
P/E ratio history for Amedisys from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 25.3 | -51.45% |
| 2020 | 52.1 | 23.29% |
| 2019 | 42.3 | 31.71% |
| 2018 | 32.1 | -45.22% |
| 2017 | 58.6 | 53.87% |
| 2016 | 38.1 | -110.65% |
| 2015 | -357 | -574.98% |
| 2014 | 75.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 LHC Group LHCG | 82.4 | 208.01% | 🇺🇸 USA |
 National Healthcare
NHC | 51.8 | 93.69% | 🇺🇸 USA |
 Chemed CHE | 33.8 | 26.15% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.